Therapeutic strategies for Alzheimer’s disease in clinical trials
暂无分享,去创建一个
Jakub Jończyk | Dawid Panek | Justyna Godyń | Barbara Malawska | B. Malawska | Jakub Jończyk | Justyna Godyń | Dawid Panek
[1] J. Fuentealba,et al. ATP leakage induces P2XR activation and contributes to acute synaptic excitotoxicity induced by soluble oligomers of β-amyloid peptide in hippocampal neurons , 2016, Neuropharmacology.
[2] P. Moreau,et al. Frontline therapy of multiple myeloma. , 2015, Blood.
[3] Anil Kumar,et al. A review on Alzheimer’s disease pathophysiology and its management: an update , 2015, Pharmacological reports : PR.
[4] C. Holmes,et al. Effect of active Aβ immunotherapy on neurons in human Alzheimer's disease , 2015, The Journal of pathology.
[5] M. Youdim,et al. New Approaches to Treating Alzheimer’s Disease , 2015, Perspectives in medicinal chemistry.
[6] F. Grüninger. Invited review: Drug development for tauopathies , 2015, Neuropathology and applied neurobiology.
[7] Dawid Panek,et al. Recent Development of Multifunctional Agents as Potential Drug Candidates for the Treatment of Alzheimer's Disease , 2014, Current medicinal chemistry.
[8] B. Dubois,et al. A phase II trial of tideglusib in Alzheimer's disease. , 2015, Journal of Alzheimer's disease : JAD.
[9] R. Vassar. BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease , 2014, Alzheimer's Research & Therapy.
[10] J. Götz,et al. Tau aggregation and its interplay with amyloid-β , 2014, Acta Neuropathologica.
[11] M. Sabbagh,et al. Neuropathological and biochemical assessments of an Alzheimer's disease patient treated with the γ-secretase inhibitor semagacestat. , 2014, American journal of neurodegenerative disease.
[12] L. Schneider. Idalopirdine for Alzheimer's disease: written in the stars , 2014, The Lancet Neurology.
[13] Kristian Windfeld,et al. Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial , 2014, The Lancet Neurology.
[14] N. Greig,et al. Lessons from a BACE1 inhibitor trial: Off-site but not off base , 2014, Alzheimer's & Dementia.
[15] R. Segurado,et al. NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease , 2014, BMJ Open.
[16] H. Qing,et al. Potential Therapeutic Strategies for Alzheimer's Disease Targeting or Beyond β-Amyloid: Insights from Clinical Trials , 2014, BioMed research international.
[17] J. Cummings,et al. Alzheimer’s disease drug-development pipeline: few candidates, frequent failures , 2014, Alzheimer's Research & Therapy.
[18] I. Mook‐Jung,et al. Diverse Molecular Targets for Therapeutic Strategies in Alzheimer's Disease , 2014, Journal of Korean medical science.
[19] S. Dutta,et al. The H3 antagonist ABT-288 is tolerated at significantly higher exposures in subjects with schizophrenia than in healthy volunteers. , 2014, British journal of clinical pharmacology.
[20] B. Winblad,et al. The battle of Alzheimer’s Disease – the beginning of the future Unleashing the potential of academic discoveries , 2014, Front. Pharmacol..
[21] N. Relkin. Clinical Trials of Intravenous Immunoglobulin for Alzheimer’s Disease , 2014, Journal of Clinical Immunology.
[22] A. Fleisher,et al. The Alzheimer's prevention initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer's disease treatments in presenilin 1 E280A mutation carriers. , 2014, The Journal of clinical psychiatry.
[23] Thomas Wisniewski,et al. Immunotherapy for Alzheimer's disease. , 2014, Biochemical pharmacology.
[24] George Perry,et al. The complexities of the pathology-pathogenesis relationship in Alzheimer disease. , 2014, Biochemical pharmacology.
[25] C. Harrington,et al. Tau-aggregation inhibitor therapy for Alzheimer's disease. , 2014, Biochemical pharmacology.
[26] Young Chul Youn,et al. The genetics of Alzheimer’s disease , 2014, Clinical interventions in aging.
[27] J. Karlawish,et al. The A4 Study: Stopping AD Before Symptoms Begin? , 2014, Science Translational Medicine.
[28] R. Vassar,et al. Targeting the β secretase BACE1 for Alzheimer's disease therapy , 2014, The Lancet Neurology.
[29] E. Siemers,et al. Amyloid-ß-directed immunotherapy for Alzheimer's disease , 2014, Journal of internal medicine.
[30] G. Logroscino,et al. Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease? , 2014, Current opinion in psychiatry.
[31] N. Andreasen,et al. Pathways to Alzheimer's disease , 2014, Journal of internal medicine.
[32] P. Mecocci,et al. Clinical trials and late‐stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014 , 2014, Journal of internal medicine.
[33] G. Logroscino,et al. Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward , 2014, Expert review of clinical immunology.
[34] R. Raffa,et al. Potential novel targets for Alzheimer pharmacotherapy: II. Update on secretase inhibitors and related approaches , 2014, Journal of clinical pharmacy and therapeutics.
[35] A. Roses,et al. New applications of disease genetics and pharmacogenetics to drug development. , 2014, Current opinion in pharmacology.
[36] Abbas Ali Mahdi,et al. Therapeutics of Alzheimer's disease: Past, present and future , 2014, Neuropharmacology.
[37] E. Siemers,et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. , 2014, The New England journal of medicine.
[38] M. Sabbagh,et al. Effect of TTP488 in patients with mild to moderate Alzheimer’s disease , 2014, BMC Neurology.
[39] G. Rutigliano,et al. The 5-HT6 receptor antagonism approach in Alzheimer's disease , 2014, Drugs of the Future.
[40] P. Maruff,et al. A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer's disease. , 2014, Current Alzheimer Research.
[41] A. Othman,et al. A randomized study of H3 antagonist ABT-288 in mild-to-moderate Alzheimer's dementia. , 2014, Journal of Alzheimer's disease : JAD.
[42] Modulation of β-amyloid by a single dose of GSK933776 in patients with mild Alzheimer’s disease: a phase I study , 2014, Alzheimer's Research & Therapy.
[43] D. Galimberti,et al. Disease-modifying drugs in Alzheimer’s disease , 2013, Drug design, development and therapy.
[44] T. Golde,et al. γ-Secretase inhibitors and modulators. , 2013, Biochimica et biophysica acta.
[45] M N Rossor,et al. Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. , 2013, Revue neurologique.
[46] E. Marcello,et al. ADAM10 in Synaptic Physiology and Pathology , 2013, Neurodegenerative Diseases.
[47] F. van Leuven,et al. Efficacy and Safety of A Liposome-Based Vaccine against Protein Tau, Assessed in Tau.P301L Mice That Model Tauopathy , 2013, PloS one.
[48] E. Siemers,et al. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. , 2013, The New England journal of medicine.
[49] B. Dubois,et al. A phase II randomized, double-blind, parallel group, 26-week study of GSK-3 inhibitor tideglusib in Alzheimer's disease (ARGO trial) , 2013, Alzheimer's & Dementia.
[50] D. Wilkinson,et al. A clinical phase II study of Lu AE58054 added to stable donepezil treatment in patients with moderate Alzheimer's disease , 2013, Alzheimer's & Dementia.
[51] E. Liu,et al. Safety, tolerability and immunogenicity of an immunotherapeutic vaccine (vanutide cridificar [ACC-001]) and the QS-21 adjuvant in Japanese individuals with mild-to-moderate Alzheimer's disease: A phase IIa, multicenter, randomized, adjuvant and placebo clinical trial , 2013, Alzheimer's & Dementia.
[52] A. Roses,et al. Using Genetics to Enable Studies on the Prevention of Alzheimer's Disease , 2013, Clinical pharmacology and therapeutics.
[53] M. Pai,et al. Exacerbation of psoriatic skin lesions in a patient with Alzheimer disease receiving gamma-secretase inhibitor. , 2013, Journal of the American Academy of Dermatology.
[54] John Bond,et al. The worldwide economic impact of dementia 2010 , 2013, Alzheimer's & Dementia.
[55] Xuefeng Yu,et al. Intranasal insulin ameliorates tau hyperphosphorylation in a rat model of type 2 diabetes. , 2012, Journal of Alzheimer's disease : JAD.
[56] David J. Fleet,et al. Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study. , 2012, Journal of Alzheimer's disease : JAD.
[57] Suzanne Craft,et al. Sex and ApoE genotype differences in treatment response to two doses of intranasal insulin in adults with mild cognitive impairment or Alzheimer's disease. , 2013, Journal of Alzheimer's disease : JAD.
[58] A. Gjedde,et al. Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer´s disease - protocol for a controlled, randomized double-blinded trial. , 2012, Danish medical journal.
[59] Min Zhang,et al. Pharmacological Properties and Procognitive Effects of ABT-288, a Potent and Selective Histamine H3 Receptor Antagonist , 2012, Journal of Pharmacology and Experimental Therapeutics.
[60] M. Pangalos,et al. Treatment strategies targeting amyloid β-protein. , 2012, Cold Spring Harbor perspectives in medicine.
[61] Nick C Fox,et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. , 2012, The New England journal of medicine.
[62] Ole A. Andreassen,et al. A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline , 2012, Nature.
[63] R. Mayeux,et al. Epidemiology of Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.
[64] U. Schepers,et al. Secretome protein enrichment identifies physiological BACE1 protease substrates in neurons , 2012, The EMBO journal.
[65] K. Blennow,et al. Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study , 2012, The Lancet Neurology.
[66] Bikram Singh,et al. Thalidomide: chemistry, therapeutic potential and oxidative stress induced teratogenicity. , 2012, Current topics in medicinal chemistry.
[67] N. Greig,et al. Early intervention with a small molecule inhibitor for tumor nefosis factor-α prevents cognitive deficits in a triple transgenic mouse model of Alzheimer’s disease , 2012, Journal of Neuroinflammation.
[68] A. Roses,et al. Characterization of the Poly-T Variant in the TOMM40 Gene in Diverse Populations , 2012, PloS one.
[69] D. Bertrand,et al. EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors , 2012, Neuropharmacology.
[70] R. Mahley,et al. Small Molecule Structure Correctors Abolish Detrimental Effects of Apolipoprotein E4 in Cultured Neurons* , 2011, The Journal of Biological Chemistry.
[71] B. Hyman,et al. Neuropathological alterations in Alzheimer disease. , 2011, Cold Spring Harbor perspectives in medicine.
[72] J. Morris,et al. Alzheimer’s Disease: The Challenge of the Second Century , 2011, Science Translational Medicine.
[73] D. Kovacs,et al. The many substrates of presenilin/γ-secretase. , 2011, Journal of Alzheimer's disease : JAD.
[74] S. Morisset,et al. [The histaminergic system: a target for innovative treatments of cognitive deficits]. , 2010, Therapie.
[75] M. Gold,et al. Double-blind, controlled phase II study of a 5-HT6 receptor antagonist, SB-742457, in Alzheimer's disease. , 2010, Current Alzheimer research.
[76] M. Solas,et al. Signalling pathways associated with 5-HT6 receptors: relevance for cognitive effects. , 2010, The international journal of neuropsychopharmacology.
[77] J. Arrang,et al. [The histaminergic system: a target for innovative treatments of cognitive deficits]. , 2010, Therapie.
[78] Talib F. Abbas,et al. Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease , 2009, Behavioural Brain Research.
[79] T. Gómez-Isla,et al. A novel GSK-3β inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo , 2009, Neurobiology of Disease.
[80] M. Novák. Tau vaccine: Active immunization with misfolded tau protein attenuates tau pathology in the transgenic rat model of tauopathy , 2009, Alzheimer's & Dementia.
[81] F. Gil-Bea,et al. Effects of 5‐HT6 receptor antagonism and cholinesterase inhibition in models of cognitive impairment in the rat , 2008, British journal of pharmacology.
[82] K. Browman,et al. The histamine H3 receptor: an attractive target for the treatment of cognitive disorders , 2008, British journal of pharmacology.
[83] P. Mehta,et al. Intranasal insulin improves cognition and modulates β-amyloid in early AD , 2008, Neurology.
[84] G. Schellenberg,et al. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. , 2008, Journal of Alzheimer's disease : JAD.
[85] B. Imbimbo. Therapeutic potential of gamma-secretase inhibitors and modulators. , 2008, Current topics in medicinal chemistry.
[86] M. Reger,et al. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. , 2008, Neurology.
[87] A. Astell,et al. Molecular connexions between dementia and diabetes , 2007, Neuroscience & Biobehavioral Reviews.
[88] D. Lockwood,et al. The role of thalidomide in the management of erythema nodosum leprosum. , 2007, Leprosy review.
[89] T. Golde. The Pathogenesis of Alzheimer's Disease and the Role of Aβ42 , 2007, CNS Spectrums.
[90] P. Saftig,et al. Control of Peripheral Nerve Myelination by the ß-Secretase BACE1 , 2006, Science.
[91] . Global prevalence of dementia: a Delphi consensus study , 2006 .
[92] D. M. Robinson,et al. Memantine: a review of its use in Alzheimer's disease. , 2006, Drugs.
[93] Chi Li,et al. Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[94] N. Greig,et al. Thalidomide-based TNF-alpha inhibitors for neurodegenerative diseases. , 2004, Acta neurobiologiae experimentalis.
[95] K. Blennow,et al. Intrathecal inflammation precedes development of Alzheimer’s disease , 2003, Journal of neurology, neurosurgery, and psychiatry.
[96] W. Banks,et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection , 2003, Nature Medicine.
[97] G. Rubin,et al. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[98] D. Cleveland,et al. Going new places using an old MAP: tau, microtubules and human neurodegenerative disease. , 2001, Current opinion in cell biology.
[99] S. Artavanis-Tsakonas,et al. Notch signaling: cell fate control and signal integration in development. , 1999, Science.
[100] E Lai,et al. A 4-Mb high-density single nucleotide polymorphism-based map around human APOE. , 1998, Genomics.
[101] J. Haines,et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.
[102] M A Pericak-Vance,et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. , 1993, Neurology.
[103] J. Hardy,et al. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. , 1991, Trends in pharmacological sciences.
[104] P. Davies,et al. SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE , 1976, The Lancet.